Search clinical trials for: CoFactor

Total 2760 results

Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years

Haemophilia B

Poland, Ukraine
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B

Haemophilia B

United Kingdom
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Chinese PLA General Hospital

Unknown

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Non-healing Wounds

Mesenchymal Stem Cell-derived Bioactivator for Treating Chronic Wounds

China
Tulane University
Genentech, Inc.

Recruiting

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Hemophilia A

United States
Nationwide Children's Hospital

Suspended

Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A

Charcot-Marie-Tooth Neuropathy Type 1A

United States
Masaryk Hospital Krajská zdravotní a.s.

Completed

Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma

Coagulation Disorder | Multiple Trauma | Coagulation Defect; Acquired | Coagulation Factor Deficiency

Czechia
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Cooperative Study of Factor VIII Inhibitors

Hematologic Diseases | Hemophilia A | Blood Coagulation Disorders | Hemorrhagic Disorders
University of Pennsylvania

Completed

Factor V Leiden Mutation and Implantation Failure

Infertility

United States
Ege University

Completed

Effect of CGF on Short Term Clinical Outcomes After Partially Impacted Mandibular Third Molar Surgery (CGF)

Edema | Postoperative Pain | Trismus

Turkey
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

Hemophilia A

Canada
Queen's University, Belfast
Western Health and Social Care Trust

Completed

Border Region Area Lifestyle Intervention Study for Healthy Neurocognitive Ageing Diabetes

Diabetes Mellitus, Type 2

United Kingdom
4Life Research, LLC
St. Louis University; Professional Athletic Orthopedics

Completed

Gold Factor on Knee Joint Health and Function

Rheumatoid Arthritis | Knee Osteoarthritis | Knee Arthritis | Knee Discomfort | Knee Pain Chronic | Knee Pain Swelling

United States
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Assiut University

Unknown

The Role of C1q Tumor Necrosis Factor-related Protein 6 in Breast Cancer

Breast Cancer
Christopher O'Brien, MD
BioIncept LLC

Withdrawn

Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies

Panel Reactive Antibodies
Hospital Universitario La Fe

Unknown

Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients

Hemophilia A | Factor VIII

Spain
Virginia Commonwealth University

Withdrawn

Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors

Malignant Childhood Neoplasm | Childhood Hodgkin Lymphoma | Childhood Brain Tumor | Childhood Non-Hodgkin Lymphoma
Novo Nordisk A/S

Withdrawn

Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B
Sheba Medical Center

Unknown

A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery (rFVIIa)

Hemophilia C

Israel
West China Hospital

Recruiting

Effect of Concentrated Growth Factors on Healing of Apicomarginal Defects: a Prospective Study

Bone Substitute | Concentrated Growth Factor

China
Necmettin Erbakan University

Completed

Evaluation of the Effect of Periimplant Soft Tissue Phenotype on Marginal Bone Loss

Dental Implant | Alveolar Bone Loss | Periimplantitis

Turkey
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Baxalta now part of Shire

Active, not recruiting

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Hemophilia A

Spain, Thailand, Hungary, Taiwan, Korea, Republic of, Czechia, Germany, Sweden, Italy, Croatia, United States, Bulgaria, Netherlands
Pfizer

Active, not recruiting

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (AFFINE)

Hemophilia A

Spain, Taiwan, Australia, United States, Japan, France, Turkey, Germany, Korea, Republic of, United Kingdom, Saudi Arabia, Canada, Greece, Sweden, Brazil, Italy
Peking University Third Hospital

Completed

The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine

Spinal Tumor

China
Joseph Broderick, MD
Novo Nordisk A/S; National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (FASTEST)

Intracerebral Hemorrhage

United States, Canada, Germany, Japan, Spain, United Kingdom
Zhejiang University

Completed

Split or Whole Liver Transplantation? A Multicenter Retrospective Cohort Study of Patients With Benign and Malignant Liver Disease

Zhejiang University

China
Prothya Biosolutions
PRA Health Sciences

Completed

Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation

Healthy Volunteers

Netherlands
York University
Government of Nunavut; Qaujigiartiit Health Research Centre

Completed

Making SPARX Fly in Nunavut: Pilot Testing an E-intervention for Boosting Resilience Against Youth Depression

Depressive Symptoms | Emotion Regulation

Canada
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Hemophilia A | Hemophilia B

United States, Australia, China, Denmark, France, Israel, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Germany, India, South Africa, Spain, Taiwan, Hungary, Italy
University of Nevada, Reno

Completed

Growth Mindset Psychoeducation for Modifiable Risk Factors for CMD

Depression, Anxiety

United States
D'Youville College

Completed

CVD Risk Factor Knowledge Across Age Groups

Cardiovascular Risk Factor
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

Israel, Sweden, United Kingdom, Germany, Switzerland, France, Spain, Italy, Thailand, Denmark, United States, Poland, Finland, Singapore, Australia, Austria
Merck KGaA, Darmstadt, Germany

Completed

r-hLIF for Improving Embryo Implantation in IVF

Infertility Implantation Failure
Merck KGaA, Darmstadt, Germany

Completed

A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure

Infertility Implantation Failure
University of Virginia
Pfizer; Astellas Pharma Inc; National Institutes of Health (NIH)

Unknown

Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus

Type 2 Diabetes | Microvascular Dysfunction

United States
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Hemophilia A

United States, France, United Kingdom, Spain, Germany, Canada, Puerto Rico, Italy, Sweden, Austria
Chinese PLA General Hospital

Unknown

Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Residual Burn Wound

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Residual Burn Wound

China
Green Cross Corporation
Atlantic Research Group

Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States, Canada, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
University of Nevada, Reno

Completed

Single Session Intervention to Prevent Common Mental Disorders and Among College Students

Depression, Anxiety

United States
Chinese PLA General Hospital
Gansu Provincial Maternity and Child-Care Hospital

Unknown

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision

MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision
Novo Nordisk A/S

Terminated

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

United States
Novo Nordisk A/S

Completed

Use of Activated Recombinant FVII in Spinal Surgery

Spinal Fusion | Acquired Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Japan

Search clinical trials for: CoFactor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations